Interest in the 'Test and Treat' strategy for HIV prevention among men who have sex with men living in Bangkok
RESULTS: Hepatic/Renal Toxicity
In the matched control group taking first line PEP, 3/33 experienced a ALT rise. 2 patients who initiated first line PEP were switched to raltegravir based PEP due to significant ALT rise. 0/19 who initiated on raltegravir based PEP experienced a significant ALT rise. There was no significant renal toxicity seen in either group. S/E reported appt 3 S/E reported appt 2 S/E reported appt 1
RESULTS
Between February 2010 to April 2012, 509 courses of PEP were prescribed; 33 (6.5%) were raltegravirbased PEP; 33 matched controls were identified during the same period.
•18/33 (54%) were initiated due to potential drug-drug interactions with ritonavir.
•3/33 (10%) were initiated due to the resistance profile of the contact
•12/33 (36%) were switched due to intolerance of first-line regimen
RESULTS: Drug-drug interactions
All switches to raltegravir-based PEP due to drugdrug interaction occurred by day 3 of the regimen, with 15/18 (83%) switching on day 1 of treatment. Potential drug-drug interactions included inhaled steroids such as fluticasone, herbal therapies (St Johns wort), isotretinoin, anti depressants and anti psychotics. Doctors initiated the majority of these switches, identifying the largest proportion of significant drug-drug interactions. (Figure 1 )
RESULTS: Resistance profile
All switches to raltegravir-containing PEP due to the genotypic resistance profile of the contact took place by day 3 of the course. (Figure 1 )
RESULTS: Intolerance
Switching due to drug intolerance was largely due to gastrointestinal side effects between days 1 to 16.( Figure   2 
)
Reported side effects for patients who initiated raltegravircontaining PEP were lower compared to the matched control group: 10/19 (53%) patients on raltegravircontaining PEP reported no side effects by day 28 treatment compared to 5/33 (15%) patients in the matched control group. (Figure 3, 4) 12/14 (79%) patients who were switched to raltegravircontaining PEP reported improvement in their side effects by their next appointment
RESULTS: Adherence
Self reported adherence was higher in patients who were initiated on Raltegravir based PEP:
•51% of patients matched control group reported at least one late or missed dose (n=33)
•26% of patients who initiated on raltegravir based PEP reported at least one late or missed dose (n=19)
RESULTS:Seroconversion
One patient who started first-line PEP was found to be HIV positive at baseline. An MSM who received raltegravir-containing PEP seroconverted 4.5 months after the course of PEP. He reported 3 episodes of unsafe sexual behaviour since completing PEP. None of the other patients are known to have seroconverted.
Discussion
• Prevention strategies including novel use of ARVs (PEP, Pre exposure prophylaxis & treatment for prevention) to reduce HIV incidence are becoming more important.
• This small single centre observational study suggests that Integrase inhibitors (Raltegravir) may be useful alternatives to first line PEP
• This study is however limited as is small & retrospective: larger randomised clinical trials are now needed.
• Use of newer agents e.g. integrase inhibitors may be limited by access and cost.
Key Findings
• Raltegravir based PEP appears to be better tolerated than first line PEP.
• ALT rises were seen in first line PEP but not in patients initiated on raltegravir based PEP.
• No renal toxicity was seen in either group.
• Patients who switched to raltegravir based PEP reported an improvement in tolerability.
• Higher adherence was reported in patients who initiated raltegravir based PEP.
• There were no unexplainable HIV seroconversions in patients on raltegravir based PEP. S/E reported appt 3 S/E reported appt 2 S/E reported appt 1 
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HIV-Infection during treatment of a chronic Hepatitis B Virus infection -implications for PrEP? Introduction
The application of Tenofovir disoproxil fumarate (TDF) with or without Emtricitabine (FTC) as pre-exposure prophylaxis (PrEP) may prevent HIV transmission. However, the protective effect of TDF-based PrEP differed significantly among clinical studies [1] [2] [3] , and PrEP-failure always bears the risk of inducing resistance-associated mutations due to continued exposure to antiretroviral drugs. As TDF-based PrEP might be frequently used after FDA approval, it is important to identify factors influencing PrEP-efficacy and to quantify the risk of the development of an PrEP-associated resistance mutations [4] . However, so far only poor adherence was shown to be associated with PrEP-failure [1] [2] [3] and the number of reported PrEPassociated resistance mutations is limited. Here we report the detection of TDF-resistant HIV in a Patient that acquired an HIV-infection despite monitored good adherence to a TDF-therapy of a chronic Hepatitis B Virus (HBV) infection. 
Substitutions in RT gene

Case Presentation
Routine screening for sexually transmitted infections (STI) revealed a chronic Hepatitis B virus (HBV) infection of a 25-year old MSM who was treated for an early syphilis. Due to very high HBV-DNA titers (1.78 x 10 7 IU/ml) a therapy with TDF was initiated immediately. Under TDF therapy HBV-DNA titers dropped below the detection limit within 10 months, documenting the good therapy adherence of the patient (Fig. 1A) . However, the patient did not change his risky sexual behavior as he suffered from numerous STI during the TDF-therapy (Fig. 1B) .
After negative HIV tests at the beginning of the TDF treatment and six months later, no routine HIV-tests were performed until an HIV-infection (subtype b) was confirmed during a syphilis re-infection 30 months later. At this point, TDF-resistant and TDF-susceptible HIV were simultaneously detectable (K65K/R in the genotypic resistance profile, Fig. 2 ). Retrospective analyses of frozen serum samples detected HIV-seroconversion 12 months prior to diagnosis and low HIV-RNA levels from seroconversion to diagnosis (always <400 copies/ml; Fig. 1C) . A combined antiretroviral therapy with RTV-boosted DRV, TDF and FTC was initiated and HIV-RNA levels dropped below the lower detection limit within 2 months. TDF was continued in spite of proven HIV TDF-resistance as treatment of the chronic HBV infection. 
Discussion
The TDF therapy of a chronic HBV infection in this case resembles a PrEP with TDF that should be protective against HIV infection [2] . There are several reasons that might explain the "PrEP-failure":
Lack of adherence Unlikely •The fast drop and subsequent uninterrupted suppression of HBV-DNA is an excellent marker for good therapy adherence. Transmitted drug resistance Unlikely •Transmission of K65R is extremely rare [5, 6] .
•Loss of K65R during TDF exposure is very unlikely.
•Continuously low HIV-RNA levels document a substantial effect of TDF, especially as the HLA type does not indicate, that the patient is an "elite controller" (Table 1 ; [7, 8] ).
Lack of PrEP efficacy Possible
•TDF Mono-PrEP was as effective as TDF/FTC in one study [2] . In other settings TDF/FTC was significantly more protective [4] .
•However, TDF-levels in the anal mucosa are high and should therefore protect MSM who practice receptive anal intercourse [9] . Concomitant STI Likely •STI damage the mucosal border [10] .
•STI increase the number of HIV-susceptible cells in the mucosa [10] .
•2 months before seroconversion GO was diagnosed (Fig. 1B and C) .
Conclusions
TDF/FTC has recently been approved by the FDA as PrEP against HIV for individuals with high-risk sexual behavior. However, this case suggests that concomitant STI -a considerable problem for individuals with high-risk sexual behavior -may compromise the protective effect of TDF-based PrEP. Additionally, this case illustrates the risk to induce resistance related mutations when HIV infections remain unrecognized for a prolonged time. Thus, TDF-based PrEP cannot replace but only expand other protective measures against HIV and individuals receiving PrEP must be closely monitored for PrEP failure.
